Abstract
1. We have generated monoclonal antibodies against the SARS coronavirus (SARS-CoV) X1/3a protein (3a), which are suitable for western blotting, immunocytochemistry, and immunohistochemistry. 2. We have established and characterised an in-vivo 3a transgenic Drosophila model, and demonstrated its usefulness in studying SARS-CoV 3a gene function. 3. We validated our in-vivo findings on 3a gene function in mammalian Vero E6 cells. 4. Our findings raise the possibility of using ion channel blockers as a novel approach to suppress SARS-CoV-induced cell death.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / genetics*
-
Antibodies, Monoclonal / immunology
-
Antibodies, Viral / genetics
-
Antibodies, Viral / immunology
-
Apoptosis / genetics*
-
Cell Proliferation
-
Cells, Cultured
-
Chlorocebus aethiops
-
Drosophila
-
Factor IX
-
Gene Expression Regulation, Viral*
-
Immunohistochemistry
-
Mice
-
Mice, Inbred BALB C
-
Models, Animal
-
Molecular Biology
-
Sensitivity and Specificity
-
Severe acute respiratory syndrome-related coronavirus / genetics*
-
Severe acute respiratory syndrome-related coronavirus / immunology
-
Severe acute respiratory syndrome-related coronavirus / metabolism
-
Vero Cells / cytology
-
Vero Cells / physiology
-
Viral Envelope Proteins / genetics*
-
Viral Envelope Proteins / immunology
-
Viral Envelope Proteins / metabolism
Substances
-
Antibodies, Monoclonal
-
Antibodies, Viral
-
Viral Envelope Proteins
-
Factor IX